|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.98 USD | +0.75% |
|
-.--% | - |
| 24-11-18 | Axonics, Inc.(NasdaqGS:AXNX) dropped from S&P Healthcare Equipment Select Industry Index | CI |
| 24-11-18 | Axonics, Inc.(NasdaqGS:AXNX) dropped from S&P Global BMI Index | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
Revenues | 13.82M | 112M | 180M | 274M | 366M | |||
Total Revenues | 13.82M | 112M | 180M | 274M | 366M | |||
Cost of Goods Sold, Total | 6.49M | 44.44M | 64.57M | 76.04M | 91.82M | |||
Gross Profit | 7.33M | 67.09M | 116M | 198M | 275M | |||
Selling General & Admin Expenses, Total | 67.75M | 91.68M | 139M | 196M | 235M | |||
R&D Expenses | 20.18M | 29.17M | 37.3M | 34.41M | 34.89M | |||
Amortization of Goodwill and Intangible Assets - (IS) | - | - | 7.24M | 9.38M | 9.06M | |||
Other Operating Expenses, Total | 87.93M | 121M | 183M | 240M | 279M | |||
Operating Income | -80.6M | -53.76M | -67.39M | -42.08M | -4.71M | |||
Interest Expense, Total | -2.31M | -1.87M | -7.43M | -2.43M | - | |||
Interest And Investment Income | 2.97M | 761K | 40K | 5.13M | 17.31M | |||
Net Interest Expenses | 665K | -1.11M | -7.39M | 2.7M | 17.31M | |||
Other Non Operating Income (Expenses) | - | - | - | - | - | |||
EBT, Excl. Unusual Items | -79.93M | -54.87M | -74.78M | -39.39M | 12.6M | |||
Merger & Related Restructuring Charges | - | - | -4.41M | -22.56M | -5.9M | |||
Gain (Loss) On Sale Of Assets | - | -41K | -91K | -69K | -1K | |||
Asset Writedown | - | - | - | -300K | - | |||
In Process R&D Expenses | - | - | - | - | -15.45M | |||
EBT, Incl. Unusual Items | -79.93M | -54.91M | -79.28M | -62.32M | -8.74M | |||
Income Tax Expense | 1K | 1K | 782K | -2.62M | -2.66M | |||
Earnings From Continuing Operations | -79.94M | -54.92M | -80.07M | -59.7M | -6.09M | |||
Net Income to Company | -79.94M | -54.92M | -80.07M | -59.7M | -6.09M | |||
Net Income - (IS) | -79.94M | -54.92M | -80.07M | -59.7M | -6.09M | |||
Net Income to Common Incl Extra Items | -79.94M | -54.92M | -80.07M | -59.7M | -6.09M | |||
Net Income to Common Excl. Extra Items | -79.94M | -54.92M | -80.07M | -59.7M | -6.09M | |||
Per Share Items | ||||||||
Net EPS - Basic | -2.8 | -1.48 | -1.86 | -1.28 | -0.12 | |||
Basic EPS - Continuing Operations | -2.8 | -1.48 | -1.86 | -1.28 | -0.12 | |||
Basic Weighted Average Shares Outstanding | 28.57M | 36.98M | 43.07M | 46.68M | 49.08M | |||
Net EPS - Diluted | -2.8 | -1.48 | -1.86 | -1.28 | -0.12 | |||
Diluted EPS - Continuing Operations | -2.8 | -1.48 | -1.86 | -1.28 | -0.12 | |||
Diluted Weighted Average Shares Outstanding | 28.57M | 36.98M | 43.07M | 46.68M | 49.08M | |||
Normalized Basic EPS | -1.75 | -0.93 | -1.09 | -0.53 | 0.16 | |||
Normalized Diluted EPS | -1.75 | -0.93 | -1.09 | -0.53 | 0.16 | |||
Supplemental Items | ||||||||
EBITDA | -79.41M | -52.02M | -58.27M | -30.36M | 7.78M | |||
EBITA | -80.5M | -53.66M | -60.19M | -32.7M | 4.35M | |||
EBIT | -80.6M | -53.76M | -67.39M | -42.08M | -4.71M | |||
EBITDAR | -78.06M | -49.75M | -55.88M | -27.95M | 9.5M | |||
Effective Tax Rate - (Ratio) | -0 | -0 | -0.99 | 4.2 | 30.38 | |||
Current Domestic Taxes | - | - | 211K | 76K | 409K | |||
Current Foreign Taxes | - | - | 26K | 174K | 1.43M | |||
Total Current Taxes | - | - | 237K | 250K | 1.84M | |||
Deferred Domestic Taxes | - | - | -539K | - | - | |||
Deferred Foreign Taxes | - | - | 1.08M | -2.87M | -4.5M | |||
Total Deferred Taxes | - | - | 545K | -2.87M | -4.5M | |||
Normalized Net Income | -49.96M | -34.3M | -46.74M | -24.62M | 7.88M | |||
Supplemental Operating Expense Items | ||||||||
Advertising Expense | - | 2.9M | 7.8M | 20.6M | 19.5M | |||
Selling and Marketing Expenses | 48.67M | 66.13M | 106M | 156M | 190M | |||
General and Administrative Expenses | 17.73M | 23.29M | 30.39M | 37.52M | 44.02M | |||
Research And Development Expense From Footnotes | 20.18M | 29.17M | 37.3M | 34.41M | 50.33M | |||
Net Rental Expense, Total | 1.35M | 2.26M | 2.39M | 2.41M | 1.73M | |||
Imputed Operating Lease Interest Expense | 1.02M | 1.19M | 6.78M | 4.81M | - | |||
Imputed Operating Lease Depreciation | 329K | 1.07M | -4.38M | -2.4M | - | |||
Stock-Based Comp., R&D Exp. (Total) | 1.72M | 3.46M | 5.98M | 6.73M | 9.36M | |||
Stock-Based Comp., S&M Exp. (Total) | 3.04M | 5.79M | 11.1M | 17.32M | 23.49M | |||
Stock-Based Comp., G&A Exp. (Total) | 3.95M | 5.85M | 8.08M | 7.96M | 11.69M | |||
Total Stock-Based Compensation | 8.72M | 15.1M | 25.16M | 32.02M | 44.54M |
- Stock Market
- Stocks
- AXNX Stock
- Financials Axonics, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















